Tag: Biotechnology
-
Trump signs executive order calling for fewer childhood vaccines, falsely linking shots to autism
The order builds on the Trump administration’s efforts to reshape the childhood shot schedule under HHS Secretary RFK Jr., a longtime vaccine skeptic.
-
US judge blocks Pentagon from listing WuXi as Chinese military-linked firm
The biotechnology company said in its lawsuit that its designation as a Chinese military company was arbitrary, capricious, unsupported by the facts and “the product of political pressure”.
-
The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings
As Lilly widens its lead in the obesity race, Novo is still racing to win back market share and restore investor confidence in its pipeline.
-
AstraZeneca may buck a decade of pharma strategy to buy U.S. scale
Reports of preliminary talks between AstraZeneca and Bristol Myers Squibb moved shares and reignited debate over Big Pharma consolidation.
-
Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
Eli Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from a previous guidance of $82 billion and $85 billion.
-
CVS blows past estimates, hikes guidance as insurance unit continues to improve
CVS also announced a new collaboration with Eli Lilly that will make Zepbound and Foundayo accessible to eligible patients on the CVS Health app.
-
Pfizer tops estimates, hikes low end of revenue guidance on strength of Eliquis, other drugs
Pfizer said it cut its full-year revenue expectation for its Covid products to $4 billion, down from around $5 billion previously.
-
Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal charges
Merck cut its profit guidance due to a charge tied to its acquisition of biotech company Terns Pharmaceuticals.
-
Humana tops quarterly estimates, maintains profit outlook as medical costs stay in line
Humana maintained its 2026 adjusted profit outlook of at least $9 per share, which some analysts called a “disappointment” amid high expectations for insurers.
-
Jim Cramer: J&J talc settlement is good for a stock that has so much going for it already
Jim Cramer described the recent trading action on Wall Street as a “J&J market.”
Latest News
Stay Connected
Categories
BBC News CNA CNBC CNN International Deutsche Welle (DW) Euronews France 24 General Global & European Specialized & Regional
Tags
amp Artificial intelligence Asia Breaking News: Business Breaking News: Markets Breaking News: Politics Breaking News: Technology Business business news cent china cup Donald J. Trump Donald Trump economy European Union fast football France germany india Investment strategy iran Iran war markets People per politics return russia S&P 500 Index said Singapore spain Sport Stock markets technology trump ukraine United States US-Israel attack on Iran 2026 video War in Ukraine World World Cup 2026
About the Author
AF themes
Easy WordPress Websites Builder: Versatile Demos for Blogs, News, eCommerce and More – One-Click Import, No Coding! 1000+ Ready-made Templates for Stunning Newspaper, Magazine, Blog, and Publishing Websites.
Search the Archives
Access over the years of investigative journalism and breaking reports
You May Have Missed
